Skip to main content

Table 1 Baseline demographic and clinical characteristics of all included patients

From: Effect of eradication of HCV infection by direct-acting antivirals in diabetic HCV-infected patients as regards glycemic control

  Glycemic non-improved
Patients (no = 53)
Glycemic improved
Patients (no = 32)
P value
Male, n (%) 21(39.6%) 12(37.5%) 0.846
Age (year)a 55.26 ± 9.24 57.50 ± 7.37 0.248
Insulin therapy, n (%) 23(43.4%) 13(40.6%) 0.538
Oral hypoglycemic therapy, n (%) 30(56.6%) 19(59.4%) 0.538
Family history of DM, n (%) 29(54.7%) 15(46.9%) 0.483
Hemoglobin (g/dL)a 12.98 ± 1.34 13.07 ± 1.05 0.764
Leukocytes (× 103/μL cells)a 6.53 ± 1.67 6.53 ± 1.91 0.998
Platelets (× 103/μL cells)a 223.57 ± 50.09 206.56 ± 53.82 0.144
Albumin (g/dL)a 4.25 ± 0.42 4.30 ± 0.40 0.622
Bilirubin, total (mg/dL)a 0.81 ± 0.15 0.78 ± 0.22 0.436
INRa 1.29 ± 1.36 1.41 ± 1.75 0.722
AST (IU/L)a 50.65 ± 24.36 51.59 ± 28.20 0.871
ALT (IU/L)a 55.71 ± 27.48 64.13 ± 35.90 0.227
Creatinine (mg/dL)a 1.02 ± 0.86 0.87 ± 0.15 0.304
AFP (ng/mL)a 7.08 ± 5.01 7.41 ± 6.24 0.789
HCV RNA viral load (log10 IU/mL)a 6.77 ± 6.661 6.77 ± 6.640 0.847
HbA1c (%)a 8.17 ± 0.58 7.91 ± 0.69 0.062
FIB-4b scorea 1.89 ± 0.85 1.75 ± 0.76 0.442
  1. aMean ± SD. Glycemic improved group: ≥ 1% reduction of baseline HbA1c levels at SVR. Non-glycemic improved group: < 1% reduction of baseline HbA1c levels at SVR
  2. AFP Alpha-fetoprotein, ALT Alanine transaminase, AST Aspartate transaminase, bFIB-4 score = [age 3AST]/[platelets 3 ALT1/2], INR international normalized ratio, HbA1c glycated hemoglobin